20 March 2018

Ergomed plc - Notice of Preliminary Results: Date Change

 

London, UK – 20 March 2018: Ergomed plc (LSE: ERGO) ('Ergomed' or the 'Company'), a specialised pharmaceutical services and drug development company, announces that the Company will publish its Preliminary Results for the year ending 31 December 2017 on 11 April 2018.

Stephen Stamp, Chief Executive Officer, will host a presentation and conference call for analysts at 9:30am BST on the day of the results at the offices of Numis Securities, The London Stock Exchange Building, 10 Paternoster Square, London, EC4M 7LT.

 

- ENDS -

 

Enquiries:

Ergomed plc

Tel: +44 (0) 1483 503205

Stephen Stamp (Chief Executive Officer)

 

 

 

Numis Securities Limited

Tel: +44 (0) 20 7260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)

 

James Black (Joint Broker)

 

 

 

N+1 Singer

Tel: +44 (0) 20 7496 3000

Alex Price (Joint Broker)

 

 

 

Consilium Strategic Communications – for UK enquiries

Tel: +44 (0) 20 3709 5700

Chris Gardner / Mary-Jane Elliott

Ivar Milligan / Philippa Gardner

    ergomed@consilium-comms.com

 

 

MC Services – for Continental European enquiries

Tel: +49 211 5292 5222

Anne Hennecke

 

     


About Ergomed

Ergomed provides specialist services to the pharmaceutical industry and develops drugs both wholly-owned and through partnerships. Ergomed’s fast-growing, profitable service offering spans all phases of clinical development and post-approval pharmacovigilance and medical information. Drawing on more than 20 years of expertise in drug development, Ergomed is also building a growing portfolio of drug development partnerships and programmes, including wholly-owned proprietary products for the treatment of surgical bleeding. For further information, visit: http://ergomedplc.com.


Back to previous page